- Understanding the Activation of Air-Stable Ir(COD)(Phen)Cl Precatalyst for C-H Borylation of Aromatics and Heteroaromatics
-
A newly developed robust catalyst [Ir(COD)(Phen)Cl] (A) was used for the C-H borylation of three dozen aromatics and heteroaromatics with excellent yield and selectivity. Activation of the catalyst was identified by the use of catalytic amounts of water, alcohols, etc., when B2pin2 was used in noncoordinating solvents, while for THF catalytic use of HBpin was required. The results were on par with the in situ based expensive system [Ir(OMe)(COD)]2/dtbbpy or Me4Phen.
- Slack, Eric D.,Colacot, Thomas J.
-
supporting information
p. 1561 - 1565
(2021/02/20)
-
- Synthesis method of pyrazole-4-pinacolato diboron
-
The invention discloses a synthesis method of pyrazole-4-pinacolato diboron. According to the method, trimethylbenzene is added as a stable solvent during reaction, so that side reaction in the reaction process is reduced, the method is simple to operate, low in cost and easy to purify and amplify industrial production, and the technical problems that synthesis and purification of pyrazole-4-pinacolato diboron are difficult at present and the like are solved.
- -
-
Paragraph 0024-0025
(2020/02/14)
-
- 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR
-
The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
- -
-
-
- RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF
-
The present invention relates to a Rho-associated protein kinase inhibitor of Formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK).
- -
-
Paragraph 0109; 0110; 0187; 0188
(2019/01/11)
-
- RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF
-
The present invention relates to a Rho-associated protein kinase inhibitor of Formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK).
- -
-
Paragraph 0111; 0112; 0233; 0234
(2019/01/11)
-
- 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR
-
The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
- -
-
Page/Page column 33; 34
(2019/01/16)
-
- THERAPEUTIC COMPOUNDS
-
The present embodiments relate to substituted heterocyclic derivative therapeutic compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition
- -
-
Paragraph 0671; 0672
(2018/11/21)
-
- DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS
-
The present invention provides new prodrugs of therapeutically active compounds, including oligomeric prodrugs, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.
- -
-
Page/Page column 245; 324
(2018/10/19)
-
- DIHYDROQUINOLIZINONES AS ANTIVIRALS
-
Compounds, specifically hepatitis B virus and/or hepatitis D virus inhibitors, more specifically compounds that inhibit HBe antigen and HBs antigen in a subject, for the treatment of viral infections, and methods of preparing and using such compounds. Formula (I):
- -
-
Paragraph 001162; 001164; 001165
(2018/09/19)
-
- Compounds used as JAK inhibitor, and use of compounds
-
The invention provides compounds used as a JAK inhibitor, and a use of the compounds, and concretely provides compounds (represented by formula (I)) with JAK inhibition activity or a stereoisomer, a geometric isomer, a tautomer, a racemate, a nitrogen oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and a medicinal composition including the compounds. The invention also discloses a use of the compounds or the medicinal composition thereof in the preparation of medicines used for treating autoimmune diseases or proliferative diseases.
- -
-
Paragraph 0418; 0419; 0420; 0421; 0424
(2017/08/27)
-
- 3- (1H-PYRAZOL-4-YL) PYRIDINEALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR
-
The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
- -
-
-
- Thiazole kinase inhibitors
-
The invention belongs to the technical field of medicine, and particularly relates to a thiazole kinase inhibitor shown as a general formula (I), and pharmaceutically acceptable salts or stereisomers thereof, wherein R1, R2, R3, R4, m, n and p are defined
- -
-
Paragraph 0177; 0203; 0204; 0205
(2016/10/10)
-
- IMINOSUGARS USEFUL FOR THE TREATMENT OF VIRAL DISEASES
-
Formula IA, ad their use for treating viral infections.
- -
-
Page/Page column 76
(2016/06/01)
-
- THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
-
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
- -
-
Page/Page column
(2015/02/19)
-
- ARYL AMIDE KINASE INHIBITORS
-
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
- -
-
Page/Page column 185
(2015/02/02)
-
- THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF
-
Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.
- -
-
Page/Page column 67
(2015/02/19)
-
- THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
-
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
- -
-
Page/Page column 66
(2015/02/19)
-
- THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE
-
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
- -
-
Page/Page column
(2013/07/31)
-
- THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
-
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
- -
-
Page/Page column 66
(2013/07/31)
-
- ROR MODULATORS AND THEIR USES
-
The invention relates to ROR modulators; compositions comprising an effective amount of a ROR modulator; and methods for treating or preventing diseases associated with ROR.
- -
-
Paragraph 0108 - 0110
(2013/11/19)
-
- Boc groups as protectors and directors for ir-catalyzed C-H borylation of heterocycles
-
(Chemical Equation Presented) Ir-catalyzed C-H borylation is found to be compatible with Boc protecting groups. Thus, pyrroles, indoles, and azaindoles can be selectively functionalized at C-H positions β to N. The Boc group can be removed on thermolysis
- Kallepalli, Venkata A.,Shi, Feng,Paul, Sulagna,Onyeozili, Edith N.,Maleczka Jr., Robert E.,Smith III, Milton R.
-
supporting information; experimental part
p. 9199 - 9201
(2010/03/02)
-
- KINASE INHIBITOR COMPOUNDS
-
Pyridine and pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.
- -
-
Page/Page column 58
(2008/12/07)
-
- PROCESS OF MAKING CHALCOME DERIVATIVES
-
This invention is a novel methods of manufacturing chalcones that includes reacting a carbon-linked heteroaryl or heterocyclic substituted benzaldehyde with an acetophenone in a solvent or mixture of solvents in the presence of LiOMe. Also provided are new chalcones for the treatment of medical conditions.
- -
-
-